Nav: Home

Higher intensity of statin therapy associated with lower risk of death in patients with atherosclerotic cardiovascular disease

November 09, 2016

Among more than 500,000 patients with atherosclerotic cardiovascular disease, researchers found an inverse association between intensity of statin therapy and mortality, with patients who received high-intensity statins having the greatest reductions in risk of death, according to a study published online by JAMA Cardiology.

Statin therapy remains the cornerstone for the prevention of atherosclerotic cardiovascular disease (ASCVD). Many large, randomized trials have shown that the use of statins significantly reduces the likelihood of future cardiovascular events and mortality in diverse populations. Nevertheless, statin therapy in general, and high-intensity statin therapy in particular, is underused in patients with established ASCVD. The Veterans Affairs (VA) health care system has released dyslipidemia guidelines that recommend moderate-intensity statins for most patients with ASCVD, citing insufficient evidence for recommending high-intensity statin therapy except in some subgroups of patients at high risk for ASCVD.

Paul A. Heidenreich, M.D., M.S., of Stanford University, Stanford, Calif., and colleagues examined 1-year cardiovascular mortality by intensity of statin therapy among patients age 21 to 84 years with ASCVD treated in the Veterans Affairs health care system. Intensity of statin therapy was defined by the 2013 American College of Cardiology/American Heart Association guidelines, and use was defined as a filled prescription in the prior 6 months.

The study sample included 509,766 eligible adults with ASCVD at study entry (average age, 69 years), including 30 percent receiving high-intensity statin therapy (defined as atorvastatin, 40 to 80 mg, rosuvastatin, 20 to 40 mg, simvastatin, 80 mg), 46 percent receiving moderate-intensity statin therapy (atorvastatin, 10 to 20 mg, fluvastatin, 40 mg twice a day or 80 mg once a day [extended-release formulation], lovastatin, 40 mg, pitavastatin, 2 to 4 mg, pravastatin, 40 to 80 mg, rosuvastatin, 5 to 10 mg, and simvastatin, 20 to 40 mg), 6.7 percent receiving low-intensity statin therapy (fluvastatin, 20 to 40 mg, lovastatin, 20 mg, simvastatin, 10 mg, pitavastatin, 1 mg, and pravastatin, 10 to 20 mg), and 18 percent receiving no statins.

During an average follow-up of 492 days, there was a graded association between intensity of statin therapy and mortality, with 1-year mortality rates of 4 percent for those receiving high-intensity statin therapy, 4.8 percent for those receiving moderate-intensity statin therapy, 5.7 percent for those receiving low-intensity statin therapy, and 6.6 percent for those receiving no statin. The researchers also found that the maximal doses of high-intensity statins (atorvastatin, 80 mg, and rosuvastatin, 40 mg) conferred the greatest survival advantage compared with submaximal doses of high-intensity statins. The benefits of high-intensity statins were consistent for those older than 75 years compared with younger patients.

"We evaluated the real-world practice of statin use by intensity and its association with all-cause mortality in a national sample of patients with ASCVD in the VA health system. We found an inverse graded association between intensity of statin therapy and mortality. These findings suggest there is a substantial opportunity for improvement in the secondary prevention of ASCVD through optimization of intensity of statin therapy," the authors write.
(doi:10.1001/jamacardio.2016.4052. Available pre-embargo at

Editor's Note: The study was conducted using departmental funds from the Department of Medicine, Stanford University, and Medical Service, Veterans Affairs Palo Alto Health Care System. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

The JAMA Network Journals

Related Statins Articles:

Statins starve cancer cells to death
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels.
New cholesterol-lowering drug could help patients unable to take statins
A new class of oral cholesterol-lowering drug could help patients unable to take statins due to side effects.
Statins linked to higher diabetes risk
Individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes, according to an analysis published in the British Journal of Clinical Pharmacology.
Statins could protect against motor neurone disease
High cholesterol has been found to be a possible risk factor for the development of motor neurone disease (MND), according to a large study of genetic data led in the UK by Queen Mary University of London, in collaboration with the National Institutes of Health in the USA.
Statins are more effective for those who follow the Mediterranean diet
For those who have already had a heart attack or a stroke, the combination of statins and Mediterranean Diet appears to be the most effective choice to reduce the risk of mortality, especially from cardiovascular causes.
Statins have low risk of side effects
Cholesterol-lowering statin drugs are associated with a low risk of side effects.
Statins overprescribed for primary prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease.
Many older adults do not take prescribed statins properly
In a British Journal of Clinical Pharmacology study of older adults prescribed statins, first-year nonadherence and discontinuation rates were high.
Statins show little promise for conditions other than heart disease
Medicines commonly prescribed to reduce people's risk of heart attack may have limited use for treating other diseases, research suggests.
Statins associated with improvement of rare lung disease
Researchers have found that cholesterol-lowering statins may improve the conditions of people with a rare lung disease called autoimmune pulmonary alveolar proteinosis.
More Statins News and Statins Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at